Treatment of chronic hepatitis B naïve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial)Mamun Al Mahtab, Morikazu Onji, Sheikh Mohammad Fazle Akbar et al.|PLoS ONE|2018Cited by 94
Intranasal therapeutic vaccine containing HBsAg and HBcAg for patients with chronic hepatitis B; 18 months follow‐up results of phase IIa clinical studyOsamu Yoshida, Yoichi Hiasa, Sheikh Mohammad Fazle Akbar et al.|Hepatology Research|2022Cited by 24
Sustained Antiviral and Liver Protection by a Nasal Therapeutic Vaccine (NASVAC, Containing Both HBsAg and HBcAg) in Patients with Chronic Hepatitis B: 2-Year Follow-Up of Phase III Clinical TrialSheikh Mohammad Fazle Akbar, Yoichi Hiasa, Mamun Al Mahtab et al.|Pathogens|2021Cited by 24
Virus-Like Particles as vaccine antigens and adjuvants: application to chronic disease, cancer immunotherapy and infectious disease preventive strategiesGerardo Guillén, Luís Herrera, Julio Aguilar et al.|Procedia in Vaccinology|2010Cited by 21
The Safety and Efficacy of a Therapeutic Vaccine for Chronic Hepatitis B: A Follow-Up Study of Phase III Clinical TrialSheikh Mohammad Fazle Akbar, Yoichi Hiasa, Mamun Al Mahtab et al.|Vaccines|2021Cited by 21